Here is AGE's business strategy as stated in their Form 10 from last week. I totally dig they are thinking of partnering on the cell therapy programs (funding and hastening progress without share dilution) while keeping the iTR platform all to themselves (competitive advantage which can be used in multiple projects). With their primary objective being the use of "twin cell therapy and iTR products in one organ system", it would seem they are thinking of using iTR in all projects. Not only with Agex's current pipeline, but I would also wager there's at least 1 mini-pig somewhere already injected with an OpRegen/Renelon cocktail.....
Business Strategy
From our inception in August 2017, we have focused our efforts on the pre-clinical development of human therapeutics targeting aging. Our general business strategy is to initially focus our technology platform of cellular immortality and regenerative medicine on individual tissues in the body (age-related degenerative diseases such as age-related cardiovascular disease), and then expand the potential indications throughout the body affected by aging.
Our tactics in executing on this strategy include:
-> Preclinical and clinical validation of the safety and efficacy of our twin cell therapy and iTR products in one organ system;
-> Expand indications of the validated products contingent on favorable trial results;
-> Partner our cGMP clinical-grade PSCs with third parties under royalty-bearing agreements for non-core applications;
-> Build near-term revenues in our related research product and bioinformatics businesses to support the therapeutic programs; and
-> Serially partner cell therapy programs, maintaining the iTR platform as the Company’s core technology long-term.
